Turku

A new report from insurer Zurich finds that the life science sector’s greatest challenges arise only after discovery. The organizations best positioned to succeed will not necessarily be those with the most medical breakthroughs, but those that can scale up, finance, and deliver innovation reliably.

Modus Therapeutics has temporarily paused enrollment in Part 2 of its Phase IIa study of sevuparin in chronic kidney disease (CKD) with anemia after a serious adverse event in one patient. The company’s preliminary assessment is that the proof-of-concept readout will slip to the first quarter of 2027.

UK digital pathology provider Diagnexia has signed an agreement to use Swedish medical imaging IT company Sectra’s cloud-based Image Exchange Portal to receive, send and report on pathology cases from NHS organizations.

SciBase has secured its first positive US medical policy from a major Blue Cross Blue Shield organization: Highmark will cover the company’s Nevisense skin lesion assessment for patients being evaluated for possible melanoma.